Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3884586 | 0.80 | KMT2A (0.53) | KMT2APABPC1ATMPOLBALDH1A1 | |
| SCHEMBL13614048 | 0.75 | KMT2A (0.50) | KCNH2KMT2APABPC1ATMPOLB | |
| Bromide SCHEMBL1645657 | 0.67 | KMT2A (0.57) | KMT2APABPC1ATMPOLBALDH1A1 | |
| SCHEMBL13394254 | 0.66 | KMT2A (0.70) | KMT2APABPC1ATMPOLBALDH1A1 | |
| SCHEMBL12692232 | 0.65 | SMN1; SMN2 (0.63) | VCPKMT2AALDH1A1MEN1RAB9A | |
| SCHEMBL6229208 | 0.65 | KMT2A (0.48) | KMT2APABPC1ATMALDH1A1MEN1 | |
| Bromide SCHEMBL1645919 | 0.65 | KMT2A (0.73) | KMT2APABPC1ATMPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL15262009 | 0.65 | KMT2A (0.43) | KMT2APABPC1ATMPOLBALDH1A1 | |
| Bromide SCHEMBL6010154 | 0.65 | KMT2A (0.47) | KMT2APABPC1ATMPOLBALDH1A1 | |
| Bromide SCHEMBL6228655 | 0.64 | KMT2A (0.49) | KMT2APABPC1ATMPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7611546-B2 | Composition comprising at least one substituted acetylenic carbocyanin derivative, process for treating keratin fibres using it, and device therefor | L'OREAL S.A. (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090064423-A1 | Composition comprising at least one substituted acetylenic carbocyanin derivative, process for treating keratin fibres using it, and device therefor | L'OREAL S.A. (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090064423-A1 | Composition comprising at least one substituted acetylenic carbocyanin derivative, process for treating keratin fibres using it, and device therefor | KRT18, HADHB, KAT7 | KCNH2 822/4885VCP 3851/4885KMT2A 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.